RJFSA
NERV icon

Raymond James Financial Services Advisors’s Minerva Neurosciences NERV Stock Holding History

Raymond James Financial Services Advisors’s Portfolio NERV Stock Details NERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-2,500
Closed -$16K – 3421
2021
Q4 		$16K Buy
2,500
+375
+18% +$3.53K ﹤0.01% 3257
2021
Q3 		$30K Sell
2,125
-2,500
-54% -$37.6K ﹤0.01% 3216
2021
Q2 		$86K Buy
4,625
+250
+6% +$5.38K ﹤0.01% 3162
2021
Q1 		$102K Sell
4,375
-22
-0.5% -$550 ﹤0.01% 3037
2020
Q4 		$82K Buy
4,397
+9
+0.2% +$227 ﹤0.01% 2872
2020
Q3 		$112K Hold
4,388
– – ﹤0.01% 2679
2020
Q2 		$127K Buy
4,388
+1,263
+40% +$74.1K ﹤0.01% 2594
2020
Q1 		$151K Sell
3,125
-625
-17% -$37.7K ﹤0.01% 2151
2019
Q4 		$213K Buy
3,750
+625
+20% +$27.6K ﹤0.01% 2537
2019
Q3 		$194K Sell
3,125
-625
-17% -$35.4K ﹤0.01% 2514
2019
Q2 		$169K Buy
3,750
+1,250
+50% +$62.6K ﹤0.01% 2576
2019
Q1 		$157K Hold
2,500
– – ﹤0.01% 2556
2018
Q4 		$135K Buy
2,500
+625
+33% +$45.8K ﹤0.01% 2353
2018
Q3 		$188K Buy
+1,875
New +$141K ﹤0.01% 2542
2018
Q2 		– Sell
-1,750
Closed -$88K – 2834
2018
Q1 		$88K Buy
+1,750
New +$84.1K ﹤0.01% 2393

Other funds holding NERV

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SEI Investments
SEI Investments Oaks, Pennsylvania $108B AUM 26.14% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Raymond James Financial Services Advisors's NERV Position: Q1 2022 in Review

Raymond James Financial Services Advisors sold out of Minerva Neurosciences (NERV) in Q1 2022, closing a stake of 2,500 shares — an estimated $16K sold.

Raymond James Financial Services Advisors first reported a position in NERV in Q1 2018 and held it in 15 quarters. The position peaked at $213K in Q4 2019. 33 funds tracked by Wall St. Rank hold NERV as of Q1 2022.

  • Raymond James Financial Services Advisors reported no remaining Minerva Neurosciences position as of Q1 2022 after selling out during the quarter.
  • Raymond James Financial Services Advisors sold 2,500 Minerva Neurosciences shares in Q1 2022, an estimated $16K.
  • Raymond James Financial Services Advisors first reported a position in Minerva Neurosciences in Q1 2018 and held it in 15 quarters.
  • Raymond James Financial Services Advisors's Minerva Neurosciences position peaked at $213K in Q4 2019.
  • 33 funds tracked by Wall St. Rank held Minerva Neurosciences as of Q1 2022.

Based on Raymond James Financial Services Advisors's 13F filing for Q1 2022, filed 11 May 2022.